Tumor heterogeneity, which refers to variations in the cellular and genetic components between cancer cells within a tumor, can complicate the determination of optimal treatment approaches for ...

Prostate cancer (PCa) represents a highly heterogeneous disease that requires tools to assess oncologic risk and guide patient management and treatment planning. Current models are based on various ...

GG1 prostate cancer can have heterogeneous outcomes, with some patients having intermediate- or high-risk disease, challenging the notion of GG1 as uniformly low-risk. Removing the cancer label for ...

The IAEA is launching a year-long coordinated research project to develop computed tomography-based guidelines on prostate cancer contouring — a critical step in the cancer treatment process that ...

For patients with oligometastatic cancers, particularly kidney or prostate, stereotactic body radiotherapy may frequently ...

Tests do not consistently influence risk classification or treatment decisions; authors call for well-designed trials on role of GC tests in newly diagnosed PCa. (HealthDay News) — For patients with ...

A University of Kentucky Markey Cancer Center study reveals how prostate cancer cells adapt their metabolism to thrive in bone tissue, offering a potential new treatment target for patients with ...

You may have heard the saying ‘cancer is not one disease, but many diseases,’ referring to the fact that different cancers—even from the same tissue of origin—can be radically different from one ...

For more than 80 years, men have been told that testosterone fuels prostate cancer. But a more nuanced picture has emerged ...

Higher BMI statuses were associated with improved survival among patients with prostate cancer, especially those with metastatic disease. Overweight and obesity are associated with improved overall ...